These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 21240457

  • 1. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
    Zhou Q, Ching AK, Leung WK, Szeto CY, Ho SM, Chan PK, Yuan YF, Lai PB, Yeo W, Wong N.
    Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
    [Abstract] [Full Text] [Related]

  • 2. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, Zhang Y, Wang F, Chen N, Chen H, Chen Y.
    J Exp Clin Cancer Res; 2015 Oct 12; 34():118. PubMed ID: 26458953
    [Abstract] [Full Text] [Related]

  • 3. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
    Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R.
    Cancer Chemother Pharmacol; 2015 Oct 12; 76(4):699-712. PubMed ID: 26231955
    [Abstract] [Full Text] [Related]

  • 4. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, Sun HW, Hou MX, Yang YP, Feng F.
    Biochim Biophys Acta; 2016 Jul 12; 1860(7):1417-30. PubMed ID: 27091611
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
    Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, An SY, Kim JH.
    Eur J Cancer; 2014 Jan 12; 50(2):341-50. PubMed ID: 24161763
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
    Zhu D, Wu S, Hu C, Chen Z, Wang H, Fan F, Qin Y, Wang C, Sun H, Leng X, Kong D, Zhang L.
    Acta Biomater; 2017 Aug 12; 58():399-412. PubMed ID: 28627436
    [Abstract] [Full Text] [Related]

  • 8. Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy.
    Wang D, Zhang S, Zhang T, Wan G, Chen B, Xiong Q, Zhang J, Zhang W, Wang Y.
    Int J Nanomedicine; 2017 Aug 12; 12():8649-8670. PubMed ID: 29255359
    [Abstract] [Full Text] [Related]

  • 9. Radiation-guided drug delivery to mouse models of lung cancer.
    Hariri G, Yan H, Wang H, Han Z, Hallahan DE.
    Clin Cancer Res; 2010 Oct 15; 16(20):4968-77. PubMed ID: 20802016
    [Abstract] [Full Text] [Related]

  • 10. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
    Xiong Q, Cui M, Bai Y, Liu Y, Liu D, Song T.
    Colloids Surf B Biointerfaces; 2017 Jul 01; 155():93-103. PubMed ID: 28411478
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ.
    Anticancer Drugs; 2008 Oct 01; 19(9):899-909. PubMed ID: 18766004
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma.
    Jin C, Bai L, Lin L, Wang S, Yin X.
    Artif Cells Nanomed Biotechnol; 2018 Aug 01; 46(5):1076-1084. PubMed ID: 28776396
    [Abstract] [Full Text] [Related]

  • 18. Lentivirus-mediated shRNA Targeting CNN2 Inhibits Hepatocarcinoma in Vitro and in Vivo.
    Kang X, Wang F, Lan X, Li X, Zheng S, Lv Z, Zhuang Y, Zhao Y, Zhou S.
    Int J Med Sci; 2018 Aug 01; 15(1):69-76. PubMed ID: 29333089
    [Abstract] [Full Text] [Related]

  • 19. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX, Qi Y, Zhang J, Liu Y, Xu WH, Xu J, Hu HG, Wu QY, Wang Y, Zhang JP.
    Oncotarget; 2016 Nov 29; 7(48):79544-79556. PubMed ID: 27783993
    [Abstract] [Full Text] [Related]

  • 20. Induction of apoptosis by HAC-Y6, a novel microtubule inhibitor, through activation of the death receptor 4 signaling pathway in human hepatocellular carcinoma cells.
    Tsai JY, Hung CM, Bai ST, Huang CH, Chen WC, Chung JG, Kuo SC, Way TD, Huang LJ.
    Oncol Rep; 2010 Nov 29; 24(5):1169-78. PubMed ID: 20878107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.